Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy CP-870,893 + Tremelimumab
Indication/Tumor Type melanoma
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown melanoma not applicable CP-870,893 + Tremelimumab Phase I Actionable In a Phase I trial, the combination of CP-870,893 and Tremelimumab was well-tolerated, and metastatic melanoma patients treated with CP-870,893 and Tremelimumab combination therapy demonstrated an objective response rate of 27.3% (6/22; 2 complete and 4 partial responses), a median progression-free survival of 3.2 months, and median overall survival of 23.6 months, with a 45-month median follow-up (PMID: 30288340; NCT01103635). 30288340
PubMed Id Reference Title Details
(30288340) Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Full reference...